Cognito’s Proprietary Light & Sound Therapy Slows Brain Tissue Atrophy In Alzheimer’s Study

Cognito Therapeutics’s proprietary gamma sensory stimulation at 40 hertz(Hz) over a six-month period reduced white matter atrophy in the brain for individuals with Alzheimer’s Disease (AD), according to new data presented at the Alzheimer’s Association International Conference 2022.

AD is the most common form of dementia. Although white matter atrophy is observed in normal aging, it is more pronounced in those with AD. White matter degeneration, myelin loss, and oligodendrocyte damage in those with AD suggest that white matter can be a mechanistically important target for AD.

The data presented from the study and the . . .